Article Text

other Versions

PDF
Influence of age on the outcome of anti-TNFαtherapy in rheumatoid arthritis
  1. B J Radovits (b.radovits{at}reuma.umcn.nl)
  1. Radboud University Nijmegen Medical Centre, Netherlands
    1. W Kievit (w.kievit{at}reuma.umcn.nl)
    1. Radboud University Nijmegen Medical Centre, Netherlands
      1. J Fransen (j.fransen{at}reuma.umcn.nl)
      1. Radboud University Nijmegen Medical Centre, Netherlands
        1. M AFJ van der Laar (m.vandelaar{at}ziekenhuis-mst.nl)
        1. Medisch Spectrum Twente & Universiteit Twente, Netherlands
          1. T L Jansen (t.jansen{at}znb.nl)
          1. Medisch Centrum Leeuwaarden, Netherlands
            1. P LCM van Riel (p.vanriel{at}reuma.umcn.nl)
            1. Radboud University Nijmegen Medical Centre, Netherlands
              1. R FJM Laan (r.laan{at}reuma.umcn.nl)
              1. Radboud University Nijmegen Medical Centre, Netherlands

                Abstract

                Objective: To investigate the influence of age on the effectiveness and tolerance of anti-TNFα therapy in a prospective observational cohort of RA patients during the first year of anti-TNFα treatment.

                Methods: In total, 730 patients of the DREAM (Dutch Rheumatoid Arthritis Monitoring) register were categorized into three groups according to their age at the initiation of anti-TNFα therapy (<45 years, 45-65 years and >65 years). Effectiveness of anti-TNFα therapy was primarily assessed by longitudinal analysis of the DAS28 during the first 12 months of treatment. EULAR criteria for clinical response and remission, the improvement in functional capacity (HAQ) and the health-related quality of life (SF-36), tolerance of anti-TNFα therapy and treatment decisions after the cessation of anti-TNFα therapy were also analyzed.

                Results: Improvement in disease activity and physical functioning was significantly less in elderly patients, correcting for relevant confounders. Elderly patients reached the EULAR categories of good-responders and remission less often than younger patients. Drug survival, co-medication use and tolerance were comparable between the 3 age groups.

                Conclusion: Anti-TNFα therapy appeared to be less effective in elderly compared to younger RA patients, based on smaller improvements in DAS28 and HAQ and lower percentages of good response and clinical remission reached during the first 12 months of treatment.

                Statistics from Altmetric.com

                • Web only appendix 68;9:1470

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.